Biomarkers for Multiple Sclerosis and Methods of Use Thereof
AssigneesPPD Biomarker Discovery Sciences, LLC, Biogen Idec MA Inc.
InventorsAaron B. Kantor, Susan Goelz, Jun Deng, Hua Lin, Christopher Becker
Life of this patent
Estimating the term…
Abstract
Biomarkers useful for identifying treatments for and monitoring treatment of patients with multiple sclerosis (MS) are provided, as well as methods for their identification, methods of diagnosing MS, relapse of MS patients and disease progression in MS patients.
Claims70
A method to identify a composition useful for the treatment of multiple sclerosis in a subject, comprising:
- a) administering a test composition to the subject,
- b) evaluating whether administration of the test composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF;
- wherein a transient change in the biomarker indicates the test composition is useful for treatment of multiple sclerosis.
A method to identify a dose of a composition, useful for the treatment of multiple sclerosis in a subject, to elicit a desired magnitude of response;
- comprising:
- a) administering the composition to subjects at different doses, wherein the composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF;
- b) evaluating the change in the biomarker at the different doses of the composition;
- and
- c) identifying a dose of the composition that elicits the desired magnitude of response in at least one of the biomarkers.
A method to monitor treatment of a subject for multiple sclerosis, comprising:
- a) administering a therapeutic composition to the subject,
- b) evaluating whether administration of the therapeutic composition causes a transient change in a biomarker selected from the group consisting of a monocyte-associated variable, IP-10, IL-1RA, IL-18 binding protein, β-NGF, BDNF, CRP, ACT, ceruloplasmin, haptoglobin, alpha-1-acid glycoprotein, orosomucoid, serum amyloid A, a complement cascade component, VCAM, MMP, and LIF;
- wherein a transient change in the biomarker indicates efficacious treatment of multiple sclerosis.
A method to identify a composition useful for the treatment of multiple sclerosis in a subject, comprising:
- a) administering a test composition to a subject;
- b) evaluating whether the test composition causes a change in at least one of the following biomarkers on a long term basis:
- decreased NK cell counts;
- increased CD56 expression on NK cells;
- increased MCP2 expression;
- decreased CD8 T cell counts;
- normal B cell counts;
- redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects;
- decreased Apo H;
- decreased inter-alpha globulin inhibitor H1;
- decreased complement component C1s;
- increased complement component C2;
- increased Mac2 binding;
- decreased attractin-2;
- reduced B cell counts;
- reduced expression of CD38 on B cells;
- increased expression of NKB1 on NK cells;
- increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation;
- increased IL-2 production in CD4 T cells following ex vivo stimulation;
- redistribution of naïve and memory T cell subsets;
- increased soluble CD14;
- increased soluble VCAM;
- reduced MIP-1a;
- reduced IL-6R;
- reduced MCP-1;
- increased MxA;
- increased IP-10, decreased MIP-1-β;
- increased β-NGF;
- increased complement component C1s, increased complement component C1q;
- increased prothrombin;
- increased α-1 antichymotrypsin;
- decreased CALNUC;
- increased gelsolin;
- increased alpha-2 plasmin inhibitor;
- decreased fetuin-A;
- and decreased AMBP;
- wherein a change of one or more of the biomarkers indicates that the test composition is useful for treatment of multiple sclerosis.
A method to identify a dose of a composition, useful for the treatment of multiple sclerosis in a subject, to elicit a desired magnitude of response, comprising:
- a) administering a composition to subjects at different doses, wherein the composition causes a change in at least one of the following biomarkers on a long term basis:
- decreased NK cell counts;
- increased CD56 expression on NK cells;
- increased MCP2 expression;
- decreased CD8 T cell counts;
- normal B cell counts;
- redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects;
- decreased Apo H;
- decreased inter-alpha globulin inhibitor H1;
- decreased complement component C1s;
- increased complement component C2;
- increased Mac2 binding;
- decreased attractin-2;
- reduced B cell counts;
- reduced expression of CD38 on B cells;
- increased expression of NKB1 on NK cells;
- increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation;
- increased IL-2 production in CD4 T cells following ex vivo stimulation;
- redistribution of naïve and memory T cell subsets;
- increased soluble CD14;
- increased soluble VCAM;
- reduced MIP-1a;
- reduced IL-6R;
- reduced MCP-1;
- increased MxA;
- increased IP-10, decreased MIP-1-β;
- increased β-NGF;
- increased complement component C1s, increased complement component C1q;
- increased prothrombin;
- increased α-1 antichymotrypsin;
- decreased CALNUC;
- increased gelsolin;
- increased alpha-2 plasmin inhibitor;
- decreased fetuin-A;
- and decreased AMBP;
- b) evaluating the change in the biomarker at the different doses of the composition;
- and
- c) identifying a dose of the composition that elicits the desired magnitude of response in at least one of the biomarkers.
A method to monitor treatment of a subject for multiple sclerosis, comprising:
- a) administering a therapeutic composition to the subject,
- b) evaluating whether administration of the therapeutic composition causes a change in at least one of the following biomarkers on a long term basis:
- decreased NK cell counts;
- increased CD56 expression on NK cells;
- increased MCP2 expression;
- decreased CD8 T cell counts;
- normal B cell counts;
- redistribution of naïve and memory CD4 and CD8 T cell subsets compared to Naïve subjects;
- decreased Apo H;
- decreased inter-alpha globulin inhibitor H1;
- decreased complement component C1s;
- increased complement component C2;
- increased Mac2 binding;
- decreased attractin-2;
- reduced B cell counts;
- reduced expression of CD38 on B cells;
- increased expression of NKB1 on NK cells;
- increased IFNγ and IL-2 in CD8 cells following ex vivo stimulation;
- increased IL-2 production in CD4 T cells following ex vivo stimulation;
- redistribution of naïve and memory T cell subsets;
- increased soluble CD14;
- increased soluble VCAM;
- reduced MIP-1a;
- reduced IL-6R;
- reduced MCP-1;
- increased MxA;
- increased IP-10, decreased MIP-1-β;
- increased β-NGF;
- increased complement component C1s, increased complement component C1q;
- increased prothrombin;
- increased α-1 antichymotrypsin;
- decreased CALNUC;
- increased gelsolin;
- increased alpha-2 plasmin inhibitor;
- decreased fetuin-A;
- and decreased AMBP;
- wherein a long-term change in the biomarker indicates efficacious treatment of multiple sclerosis.
A method to diagnose a subject as having multiple sclerosis, comprising:
- a) analyzing a subject sample for at least one of the following biomarkers:
- i. reduced B cell counts;
- ii. reduced expression of CD38 on B cells;
- iii. increased expression of NKB1 on NK cells;
- iv. increased IFNγ and IL-2 in CD8 T cells following ex vivo stimulation;
- v. increased IL-2 production in CD4 T cells following ex vivo stimulation;
- vi. redistribution of naïve and memory T cell subsets;
- vii. increased soluble CD14;
- viii. increased soluble VCAM;
- ix. reduced MIP-1a;
- x. reduced IL-6R;
- xi. reduced MCP-1
- b) diagnosing multiple sclerosis, wherein the presence of one or more of (a)(i)-(a)(xi) indicates the subject has multiple sclerosis.
A method to diagnose relapse or disease progression in a subject having multiple sclerosis that is being treated for multiple sclerosis, comprising:
- a) analyzing a subject sample for at least one of the following biomarkers:
- i. increased MxA;
- ii. increased IP-10
- iii. decreased MIP-1-β
- iv. increased β-NGF;
- v. increased complement component C1s;
- vi. increased complement component C1q;
- vii. increased prothrombin;
- viii. increased soluble VCAM;
- ix. increased α-1 antichymotrypsin;
- x. decreased CALNUC;
- xi. increased gelsolin;
- xii. increased alpha-2 plasmin inhibitor;
- xiii. decreased fetuin-A;
- xiv. decreased AMBP;
- b) diagnosing relapse or disease progression, wherein the presence of one or more of (a)(i)-(a)(xiv) indicates the subject is in relapse or has disease progression.
Dependencies are inferred from the claim text.